Sainor Laboratories Private Limited

What Sainor Laboratories Private Limited does

Sainor Laboratories Private Limited is a Hyderabad-headquartered, founder-led specialty chemicals and pharmaceutical manufacturer incorporated in 2005, organized across three operational units. Unit I (Speciality Chemical Division, Jeedimetla) manufactures highly hazardous and pyrophoric organometallic compounds — including n-Butyllithium, Lithium HMDS, Borane derivatives, and over 217 Grignard reagents — and claims 75-80% domestic Indian market share in this niche with a zero-accident track record since inception. Unit II (Pharma Division, Jeedimetla, formerly Sainor Pharma Pvt. Ltd., established 2006) produces pharmaceutical pellets and MUPS (Multiple Unit Pellet System) tablets with delayed, extended, modified, sustained, immediate release and taste-masked profiles, certified under WHO GMP and ISO 9001:2015. Unit III (Drug Intermediate & API Division, Visakhapatnam APSEZ) extends the company into higher-value drug intermediates and APIs. The company holds ISO 14001:2015, OHSAS 18001:2007, Schedule M, and ICH certifications, supplies customers across 25+ countries including the USA, Germany, Italy, China, Japan, Brazil, and Russia, and markets through direct B2B sales backed by active participation in five major international trade shows (Cphi Milan, Cphi China, Cphi India, Chemspec Dusseldorf, IPHEX). Pricing is custom quote-based with no public disclosure, revenue is not publicly reported, and the company remains privately held with no disclosed institutional investors, PE, or VC backing.

Name

Sainor Laboratories Private Limited

Legal name

Sainor Laboratories Private Limited

Website

https://sainorlaboratories.com

Company type

Private

Founded year

2005

Operating status

Operating

Short description

Sainor Laboratories Private Limited is a Hyderabad-based specialty chemicals and pharmaceutical pellet manufacturer (founded 2005) producing organometallics, Grignard reagents, borane compounds, and controlled-release pharmaceutical pellets for B2B pharmaceutical and chemical industry customers globally.

Ownership category

akta.pro rank

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Specialty Chemicals Manufacturing: Manufacturing and sale of fine chemicals, organometallics, and specialty chemicals including lithium derivatives, borane compounds, and grignard reagents to pharmaceutical and chemical companies
2. Pharmaceutical Pellets and APIs: Manufacturing and supply of pharmaceutical pellets (MUPS, delayed release, extended release, sustained release) and drug intermediates to pharmaceutical manufacturers

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

Sainor Laboratories manufactures and supplies specialty organometallic chemicals (lithium derivatives, borane compounds, Grignard reagents, zinc chemistry) and pharmaceutical pellets for controlled-release oral dosage forms (delayed, extended, modified, sustained, immediate release, and taste-masked pellets, plus MUPS tablets). The company also produces drug intermediates and APIs. Products are sold B2B to pharmaceutical formulators, API manufacturers, and chemical industry customers globally.

Product overview

Sainor Laboratories Private Limited operates as a multi-division pharmaceutical and specialty chemicals manufacturer incorporated in 2005. The company is organized into three distinct units: Unit I (Specialty Chemicals) focuses on organometallics, Grignard reagents, borane derivatives, and lithium chemistry; Unit II (Pharma Division) manufactures pharmaceutical pellets and MUPS tablets; and Unit III (Drug Intermediate & API Division) produces drug intermediates and active pharmaceutical ingredients. The pharma pellet portfolio encompasses delayed release, extended release, modified release, sustained release, immediate release, taste mask, and blended combination pellets, serving global pharmaceutical companies with proton pump inhibitors, anti-inflammatory, antiplatelet, antidepressant, anti-fungal, and other therapeutic categories. The specialty chemicals division produces over 217 Grignard reagent products alongside n-butyllithium, lithium HMDS, borane compounds, and sodium triacetoxyborohydride, commanding 75-80% domestic market share in organometallics. The company operates manufacturing facilities in Jeedimetla, Hyderabad and Vishakapatnam, Andhra Pradesh, with global recognition across Italy, Czech Republic, Germany, Hungary, Switzerland, China, Japan, Korea, Spain, USA, Ukraine, Brazil, and other markets.

Differentiator

Problem solved

Functional benefit

Products and services

• Specialty Organometallic Chemicals (Lithium, Borane, Zinc Chemistry) Manufacturing and supply of specialty organometallic compounds including lithium derivatives (n-Butyllithium, Lithium HMDS, Lithium Amide, Lithium Methoxide, organolithium reagents), borane compounds (Borane THF, Borane-dimethylamine, Borane-dimethyl sulphide, Borane-pyridine, Borane-diphenylphosphine), and zinc-based organometallics. Sold to pharmaceutical and chemical manufacturers for organic synthesis applications.
• Grignard Reagents Manufacturing of 217+ Grignard reagent variants including alkyl, aryl, and vinyl magnesium halides in multiple molar concentrations and solvents such as THF and diethyl ether. Used for nucleophilic additions and organic synthesis in pharmaceutical and chemical industries.
• Pharmaceutical Pellets (Controlled Release) Manufacturing of pre-formulated pharmaceutical pellets including delayed release (enteric coated), extended release, modified release, sustained release, immediate release, taste-mask, and blended combination pellets across multiple therapeutic categories (proton pump inhibitors, anti-inflammatory, antiplatelet, antidepressant, anti-fungal, statins, etc.). Sold to formulation companies for capsule and tablet manufacturing under cGMP standards.
• MUPS (Multiple Unit Pellet System) Tablets
• Drug Intermediates & Active Pharmaceutical Ingredients (APIs)
• Sodium Triacetoxyborohydride (STAB)

Quantifiable outcome

• Zero accident track record since 2005
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Global Clients NetworkcoreOthersSupply relationships with pharmaceutical and chemical companies across Italy, Czech Republic, Germany, Hungary, Switzerland, China, Japan, Korea, Spain, USA, and Ukraine. B2B customer relationships for organometallics and pharmaceutical pellets.
• International Pharmaceutical CustomerscoreOthersSupply partnerships with pharmaceutical companies in India, Brazil, Uruguay, Belarus, Columbia, Thailand, Vietnam, Philippines, Kenya, Russia, Paraguay, Egypt, Hong Kong, China, Indonesia, and Bangladesh for pharmaceutical pellets and intermediates.

Scale indicators7 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Aarti Industries Limited: Largest Indian specialty chemicals and intermediates manufacturer with a diversified portfolio of APIs, intermediates, and performance chemicals. Comparable as an Indian-headquartered supplier of specialty chemicals and pharmaceutical intermediates to global pharma customers.
• Divi's Laboratories Limited: Leading Indian manufacturer of active pharmaceutical ingredients (APIs), intermediates, and nutraceutical ingredients with global supply relationships. Comparable as an Indian API and intermediate manufacturer serving global pharma with cGMP/ICH-compliant facilities.
• Albemarle Corporation: Global specialty chemicals producer including organolithium and organometallic reagents (e.g., n-Butyllithium) and lithium derivatives. Comparable as a leading global manufacturer in the same organometallic chemistry space Sainor competes in.

Direct peers

• Hikal Limited: Indian specialty chemicals manufacturer offering APIs, intermediates, and custom chemical manufacturing including complex chemistries. Comparable as a direct Indian peer in specialty fine chemicals and pharmaceutical intermediates serving global pharma.
• Laurus Labs Limited: Indian pharmaceutical company manufacturing APIs, intermediates, and formulations with global reach. Comparable as an Indian-headquartered API/intermediate and finished dosage manufacturer serving regulated pharma markets.
• Sai Life Sciences: Indian contract development and manufacturing organization (CDMO) offering API development, intermediates, and custom synthesis. Comparable as an Indian-headquartered custom synthesis and API/intermediate manufacturer for global pharma.
• Supriya Lifescience Limited: Indian manufacturer of APIs and intermediates with focus on complex chemistry and regulated markets. Comparable as an Indian API/intermediate producer with similar technical capabilities and global customer base.
• Neuland Laboratories Limited: Indian API and intermediates manufacturer offering contract manufacturing and custom synthesis services to global pharma. Comparable as a mid-sized Indian CDMO with API/intermediate focus and USFDA/EU GMP facilities.

Others

• Lupin Limited: Major Indian generic pharmaceutical company with significant API manufacturing and modified-release formulation capabilities. Comparable as a large Indian pharma player that could source pellets/intermediates from suppliers like Sainor or compete in similar therapeutic categories.

Emerging players

• Vertellus (formerly Hexion organometallics business): Global manufacturer of specialty chemicals including organometallic compounds, sodium borohydride, and pyrophoric reagents. Comparable as a direct global competitor in the organometallics and borane specialty chemistries.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/sainor-laboratories-pvt-ltd

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sainor Laboratories Private Limited